The drugmaker raised the price of a 473mL bottle of promethazine and codeine to $170.55. The cold remedy contains an antihistamine that relieves itchiness and sneezing and codeine to suppress coughing and relieve pain.
Nostrum CEO Nirmal Mulye told the Financial Times that increasing the list price of a drug was “totally meaningless.”
But often a rise in list price equates to more out-of-pocket costs for the patient.
Other drugmakers are selling the same dose of the drug at lower prices. Tris Pharma offers it for $27. and Hi-Tech Pharmacal sells it for $12.35.
“Hopefully, the price goes up, competitors raise prices, and we are able to sell some,” Mr. Mulye told the Financial Times.
Read the full report here.
More articles on pharmacy:
Insys execs guilty of opioid racketeering scheme
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
